|
13 Jul 2023 |
KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer
|
|
11 Jul 2023 |
QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
|
|
11 Jul 2023 |
Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging
|
|
10 Jul 2023 |
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors
|
|
10 Jul 2023 |
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
|
|
10 Jul 2023 |
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
|
|
08 Jul 2023 |
280 Bio receives IND approval from the FDA for YL-17231
|
|
06 Jul 2023 |
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
|
|
06 Jul 2023 |
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
|
|
06 Jul 2023 |
TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China
|
|
05 Jul 2023 |
European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to
|
|
05 Jul 2023 |
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China
|
|
04 Jul 2023 |
European Commission Grants Conditional Marketing Authorization for Taiho's LYTGOBI® Tablets for the Treatment of Adults With Cholangiocarcinoma
|
|
04 Jul 2023 |
Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
|
|
03 Jul 2023 |
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia
|
|
01 Jul 2023 |
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
|
|
01 Jul 2023 |
PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
|
|
01 Jul 2023 |
Toragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer
|
|
01 Jul 2023 |
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk
|
|
30 Jun 2023 |
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
|
|
30 Jun 2023 |
Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis
|
|
30 Jun 2023 |
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
|
|
30 Jun 2023 |
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral ALPK1 Selective Kinase Inhibitor, DF-003
|
|
30 Jun 2023 |
Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
|
|
29 Jun 2023 |
Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer
|
